Cardiff Oncology announces Phase 2 CRDF-004 data: 64% ORR in 30mg onvansertib arm vs 33% control

Cardiff Oncology, Inc.

30mg onvansertib+SoC 64% ORR (7/11) vs 33% (3/9) control; 20mg arm 50% ORR (5/10).
Onvansertib well-tolerated; no major or unexpected toxicities at either dose.
Additional CRDF-004 clinical data expected in 1H 2025.
Conference call held Dec 10, 2024 at 8:00 AM ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.